JAK inhibitor Tofacitinib citrate, Purity ≥98%

Synonym: Tofacitinib citrate; 540737-29-9; Tasocitinib citrate; Xeljanz; CP-690550 citrate; Tofacitinib (citrate); Tofacitinib (CP-690550) citrate; JAK inhibitor

MDL: MFCD11616529
CAS Number: 540737-29-9
Compound CID: 10174505

Product Size

10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Tofacitinib citrate, soluble in warmed DMSO and insoluble in water and ethanol, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, AMPK, CDK2, CDK2/CyclinA, Chk1, CK2, CSK, EGFR, GSK-3β, and IRK.

Molecular Weight

504.5

Molecular Formula

C₁₆H₂₀N₆O.C₆H₈O₇

Targets

JAK1: 112 nM; JAK2: 20 nM; AMPK: >10 μM; CDK2: >10 μM; CDK2/CyclinA: >10 μM; Chk1: >10 μM; CK2: >10 μM; CSK: >10 μM; EGFR: >10 μM; GSK-3β: >10 μM; IRK: >10 μM

Form

Lyophilized powder

Purity

≥98%

Solubility

Warmed DMSO: 94 mg/mL (186.32 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

Tofacitinib citrate is used in research focusing on its JAK1/3 inhibition properties for treating rheumatoid arthritis and other inflammatory diseases.

Storage

Store at -20ºC.